Ausgabe 3/2021
Inhalt (13 Artikel)
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Laura Cortesi, Hope S. Rugo, Christian Jackisch
Coming of Age of Immunotherapy of Urothelial Cancer
Enrique Grande, Javier Molina-Cerrillo, Andrea Necchi
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
Javier Munoz, George A. Follows, Loretta J. Nastoupil
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Giorgio Patelli, Caterina Vaghi, Federica Tosi, Gianluca Mauri, Alessio Amatu, Daniela Massihnia, Silvia Ghezzi, Erica Bonazzina, Katia Bencardino, Giulio Cerea, Salvatore Siena, Andrea Sartore-Bianchi
Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
Oluwaseun O. Akinduro, Paola Suarez-Meade, Diogo Garcia, Desmond A. Brown, Rachel Sarabia-Estrada, Steven Attia, Ziya L. Gokaslan, Alfredo Quiñones-Hinojosa
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
Kiyotaka Yoh, Tomonori Hirashima, Hideo Saka, Takayasu Kurata, Yuichiro Ohe, Toyoaki Hida, Anders Mellemgaard, Remy B. Verheijen, Xiaoling Ou, Ghada F. Ahmed, Manabu Hayama, Ko Sugibayashi, Geoffrey R. Oxnard
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
Anders Bjartell, Nicolaas Lumen, Pablo Maroto, Thomas Paiss, Francisco Gomez-Veiga, Alison Birtle, Gero Kramer, Ewa Kalinka, Dominique Spaëth, Susan Feyerabend, Vsevolod Matveev, Florence Lefresne, Martin Lukac, Robert Wapenaar, Luis Costa, Simon Chowdhury
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer
Danielle Meyrick, Marat Gallyamov, Shanthi Sabarimurugan, Nadia Falzone, Nat Lenzo
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
Thomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, Emeline Meriaux, Jérome Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte, Carlos Gomez-Roca, Paul-Arthur Haineaux, Alain Gratet, Jannick Selves, Yves Menu, Nikias Colignon, Laetitia Johnson, Frédéric Legrand, Gilles Vassal
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
Lyudmila Bazhenova, Andrew Lokker, Jeremy Snider, Emily Castellanos, Virginia Fisher, Marc Fellous, Shivani Nanda, Jihong Zong, Karen Keating, Xiaolong Jiao
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim, Caterina Vivaldi, Margherita Rimini, Giovanni Luca Frassineti, Sook Ryun Park, Mario Domenico Rizzato, Min-Hee Ryu, Francesca Salani, Ilario Giovanni Rapposelli, Baek-Yeol Ryoo, Vittorina Zagonel, Valentina Massa, Martina Valgiusti, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim, Caterina Vivaldi, Margherita Rimini, Giovanni Luca Frassineti, Sook Ryun Park, Mario Domenico Rizzato, Min-Hee Ryu, Francesca Salani, Ilario Giovanni Rapposelli, Baek-Yeol Ryoo, Vittorina Zagonel, Valentina Massa, Martina Valgiusti, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Giorgio Patelli, Caterina Vaghi, Federica Tosi, Gianluca Mauri, Alessio Amatu, Daniela Massihnia, Silvia Ghezzi, Erica Bonazzina, Katia Bencardino, Giulio Cerea, Salvatore Siena, Andrea Sartore-Bianchi